	US 12,296,066 B2
	Methods of wound healing with Serp-1 polypeptides
Alexandra Lucas, Tempe, AZ (US); Liqiang Zhang, Chandler, AZ (US); Jordan Yaron, Scottsdale, AZ (US); and Grant McFadden, Tempe, AZ (US)
Assigned to Arizona Board of Regents on Behalf of Arizona State University, Scottsdale, AZ (US)
Appl. No. 17/056,401
Filed by ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY, Scottsdale, AZ (US)
PCT Filed May 17, 2019, PCT No. PCT/US2019/032997 § 371(c)(1), (2) Date Nov. 17, 2020, PCT Pub. No. WO2019/222710, PCT Pub. Date Nov. 21, 2019.
Claims priority of provisional application 62/673,386, filed on May 18, 2018.
Prior Publication US 2021/0369910 A1, Dec. 2, 2021
Int. Cl. A61K 9/00 (2006.01); A61K 47/36 (2006.01); A61K 47/42 (2017.01); A61L 26/00 (2006.01); A61P 29/00 (2006.01); C07K 14/81 (2006.01); A61K 38/00 (2006.01)

CPC A61L 26/0066 (2013.01) [A61K 47/36 (2013.01); A61K 47/42 (2013.01); A61L 26/008 (2013.01); C07K 14/8121 (2013.01); A61K 38/00 (2013.01); A61L 2300/252 (2013.01)]

12 Claims

1. A topical formulation, comprising:

an effective amount of a Serine Protease Inhibitor-1 (Serp-1) polypeptide, wherein the Serp-1 polypeptide comprises a reactive center loop comprising an amino acid sequence of RGTTASSDTAITLIPRNALTAIVANKP (SEQ ID NO: 6), or a biologically active fragment from a reactive center loop of Serp-1, wherein the biologically active fragment comprises an amino acid sequence selected from the group consisting of IPRNAL (SEQ ID NO: 2), RNAL (SEQ ID NO: 3), TAIVANKPF (SEQ ID NO: 4), and GTTASSDTAITLIPR (SEQ ID NO: 5); and

a chitosan-collagen hydrogel containing 1 μg of the Serp-1 polypeptide or the biologically active fragment from a reactive center loop of Serp-1 per 10 μL of the chitosan-collagen hydrogel.